JMBI-001 in MYC-Positive Advanced Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early-phase interventional study investigates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JMBI-001 in adults with MYC-driven advanced tumors, including solid tumors and non-Hodgkin lymphoma. It aims to establish safe dosing for expansion and identify the recommended phase II dose, while exploring efficacy signals at the RP2D. Participants will take JMBI-001 orally on a 4-days-on, 3-days-off schedule within 21-day cycles and undergo regular safety and disease assessments. The trial will enroll across dose-escalation and expansion cohorts at a leading cancer center in China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to fully understand the study requirements, voluntarily agree to participate in the study, and provide written informed consent.
* Male or female participants aged 18 to 75 years, inclusive.
* Histologically or cytologically confirmed malignant tumor. Participants with solid tumors must have unresectable locally advanced or metastatic disease for which standard treatment has failed, is not tolerated, or is unavailable. Participants with non-Hodgkin lymphoma must have received at least two prior lines of therapy. Tumor-specific requirements for each study phase are as follows:

  1. Phase Ia dose-escalation stage: Solid tumors, including but not limited to gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and triple-negative breast cancer. Non-Hodgkin lymphoma, including but not limited to diffuse large B-cell lymphoma and Burkitt lymphoma.
  2. Phase Ib dose-expansion stage: tumor indications within prespecified tumor types of particular interest, potentially sensitive tumor types or subtypes identified during Phase Ia, or both. Prespecified tumor types of particular interest include, but are not limited to, gastric cancer, colorectal cancer, non-small cell lung cancer, hepatocellular carcinoma, and non-Hodgkin lymphoma.
  3. Phase II indication-expansion stage: selected tumor indications that meet the prespecified transition criteria during Phase Ib.
* Except for participants enrolled in the accelerated titration stage of Phase Ia, tumor tissue obtained or submitted during screening must be tested by immunohistochemistry and meet the following criteria for MYC positivity:

  1. Solid tumors: MYC-positive tumor cell nuclei in at least 10% of tumor cells.
  2. Non-Hodgkin lymphoma: MYC-positive tumor cell nuclei in at least 40% of tumor cells.
* At least one lesion suitable for efficacy assessment, as follows:

  1. For participants with solid tumors, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). The longest diameter must be at least 10 mm on spiral computed tomography, or the short-axis diameter of an enlarged lymph node must be at least 15 mm. A lesion selected as a target lesion must not have received radiotherapy within 4 weeks before the first dose of JMBI-001; palliative local radiotherapy to a non-target lesion is permitted.
  2. For participants with non-Hodgkin lymphoma, according to the Lugano 2014 criteria, the longest diameter must be greater than 1.5 cm for a nodal lesion or greater than 1.0 cm for an extranodal lesion.

Exclusion Criteria:

* Difficulty swallowing or inability to swallow tablets.
* Known hypersensitivity to any component of JMBI-001 tablets.
* Carcinomatous meningitis, brainstem metastasis, or spinal cord compression confirmed by imaging or clinical diagnosis.
* History of a severe neurologic disorder or severe psychiatric or psychological disorder that may interfere with the participant's ability to understand or comply with the study protocol.
* Systemic glucocorticoid therapy within 2 weeks before the first dose of JMBI-001 at a prednisone-equivalent dose greater than 10 mg/day.
* Gastrointestinal disease or abnormality that may affect the absorption of JMBI-001, including but not limited to celiac disease, short bowel syndrome, Crohn disease, ulcerative colitis, gastrointestinal perforation, or severe vomiting or diarrhea.

Other Inclusion/exclusion criteria may apply.

Where it's running

• Peking University Cancer Hospital & Institute
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Clinical Trial Information Team
• Email: JMBIClinicalTrials@anticancerbio.com
• Phone: +86 28 85185225

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• INV-8989 in KRAS G12D-mutant advanced solid tumors

  This study tests INV-8989 to see if it can be safely given and potentially help patients with KRAS G12D-mutant advanced solid tumors.

  Recruiting Phase 1/2 Shenzhen Ionova Life Sciences Co., Ltd. · Guangzhou, Guangdong · NCT07610798

• GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

  We’re testing whether GSK5926371 is safe and can show activity in adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatment.

  Recruiting at 22 sites Phase 1/2 GlaxoSmithKline · Iowa City, Iowa and 21 other locations · NCT07607925

• AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients

  This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.

  Recruiting Grand Hôpital de Charleroi · Charleroi, Hainaut · NCT07546188

• MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma

  This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.

  Recruiting at 54 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 53 other locations · NCT07519772

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.